Effectiveness of Carboplatin (C) plus weekly docetaxel (D) as second-line treatment for docetaxel-resistant, hormone-refractory prostate cancer (HRPC)

被引：0
|
作者：
Reuter, C. W. M. [1 ]
Morgan, M. A. [1 ]
Winkler, T. [1 ]
Fenner, M. [1 ]
Ganser, A. [1 ]
Gruenwald, V. [1 ]
机构：
[1] Hannover Med Sch, D-3000 Hannover, Germany
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)71424-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：420 / 420
页数：1
相关论文
共 50 条
  • [1] High efficacy of carboplatin (C) plus weekly docetaxel (D) as second-line treatment for docetaxel-resistant, hormone-refractory prostate cancer (HRPC)
    Reuter, C. W. M.
    Morgan, M.
    Fenner, M.
    Winkler, T.
    Ganser, A.
    Gruenwald, V.
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2009, 72 : S39 - S39
  • [2] Outcome of second-line chemotherapy with a combination of docetaxel and carboplatin (DC) in docetaxel-resistant (DR) hormone refractory prostate cancer (HRPC) patients
    Gruenwald, V.
    Ivanyi, P.
    Winkler, T.
    Morgan, M.
    Fenner, M.
    Ganser, A.
    Reuter, C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] Carboplatin plus weekly docetaxel as second-line chemotherapy in docetaxel-resistant and castration-resistant prostate cancer (CRPC).
    Reuter, C. W.
    Gruenwald, V.
    Ivanyi, P.
    Morgan, M. A.
    Fenner, M.
    Ganser, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Biweekly doxorubicin/ketoconazole as second-line treatment in docetaxel-resistant, hormone-refractory prostate cancer
    Lainakis, George
    Nikos, Antoniou
    Gerassimos, Allvizatos
    Michael, Chrisofos
    Iraklis, Mitsoyiannis
    Konstantinos, Livadas
    Ioannis, Varkarakis
    Harilaos, Katsifotis
    Dimopoulos, Meletios A.
    Bamias, Aristotelis
    [J]. UROLOGY, 2008, 71 (06) : 1181 - 1185
  • [5] Second line chemotherapy with estramustine (E) plus docetaxel(D) in patients with hormone-refractory prostate cancer (HRPC), resistant to docetaxel alone
    Caffo, Orazio
    Sava, Teodoro
    Comploj, Evi
    Segati, Romana
    Giampaolo, Marianna
    Valduga, Francesco
    Caldara, Alessia
    Galligioni, Enzo
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : 70 - 70
  • [6] High response to docetaxel (D)/carboplatin (C) based chemotherapy as salvage therapy in patients with docetaxel-resistant metastastic hormone-refractory prostate cancer (HRPC)
    Reuter, C.
    Ivanyi, P.
    Morgan, M.
    Ganser, A.
    Winkler, T.
    Fenner, M.
    Gruenwald, V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] Hormonal Impact of Second-line Salvage Chemotherapy With Carboplatin Plus Weekly Docetaxel in Patients With Castration and Docetaxel-resistant Prostate Cancer
    Reuter, C.
    Morgan, M.
    Fenner, M.
    Ivanyi, P.
    Gruenwald, V.
    Ganser, A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S501 - S501
  • [8] Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone
    Caffo, Orazio
    Sava, Teodoro
    Comploj, Evi
    Giampaolo, Maria Anna
    Segati, Romana
    Valduga, Francesco
    Cetto, Gianluigi
    Galligioni, Enzo
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2010, 28 (02) : 152 - 156
  • [9] Weekly docetaxel for advanced hormone-refractory prostate cancer-HRPC
    Pepe, A.
    Usset, A.
    Calabria, C.
    Savio, G.
    Palmisano, V
    Leonardi, V
    Laudani, A.
    Arcuri, C.
    Giresi, A.
    Agostara, B.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : XI82 - XI82
  • [10] Weekly docetaxel for advanced hormone-refractory prostate cancer-hrpc
    Pepe, A.
    Usset, A.
    Calabria, C.
    Savio, G.
    Palmisano, V
    Leonardi, V
    Laudani, A.
    Arcuri, C.
    Agostara, B.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : 187 - 187
12345